Key Takeaways

TB-500 is commonly described as a recovery or wound-healing peptide, but the most important scientific distinction is that the marketed compound is usually a short synthetic fragment of thymosin β4, not the full-length thymosin β4 molecule studied in several human ophthalmic and tissue-repair programs.
The biology behind thymosin β4 is real and includes actin binding, cell migration, inflammation modulation, and wound-repair pathways, but that does not mean injected TB-500 fragment has been clinically proven to improve musculoskeletal recovery in humans.
The strongest human evidence belongs mostly to full-length thymosin β4 in specific formulations, such as ophthalmic RGN-259, while the gray-market TB-500 use case remains largely animal-model, mechanistic, and anecdotal.
TB-500 is therefore best described as investigational, unapproved, and scientifically plausible in limited contexts, not as a proven healing or recovery treatment.

‍

_{[FDA, 2026; Van Troys et al., 1996; Sosne et al., 2022; Scientific American, 2026; Vox, 2026].}

‍

TB-500: A synthetic peptide fragment commonly described as Ac-LKKTETQ. Corresponds to residues 17 to 23 of full-length thymosin β4, but is not the same molecule as the endogenous 43 amino acid parent protein that much of the human literature actually studied.

Overview

TB-500 is commonly described as a recovery or wound-healing peptide, but the most important scientific distinction is that the marketed compound is usually a short synthetic fragment of thymosin β4, not the full-length thymosin β4 molecule studied in several human ophthalmic and tissue-repair programs. The biology behind thymosin β4 is real and includes actin binding, cell migration, inflammation modulation, and wound-repair pathways, but that does not mean injected TB-500 fragment has been clinically proven to improve musculoskeletal recovery in humans. The strongest human evidence belongs mostly to full-length thymosin β4 in specific formulations, such as ophthalmic RGN-259, while the gray-market TB-500 use case remains largely animal-model, mechanistic, and anecdotal. For TB-500 free base and acetate themselves, FDA's 2026 review identified no human administration data and no in vivo wound-healing studies; the direct scientific evidence remains limited to in vitro findings and nonclinical pharmacokinetics. TB-500 is therefore best described as investigational, unapproved, and scientifically plausible in limited contexts, not as a proven healing or recovery treatment. [FDA, 2026; FDA TB-500 briefing document; Van Troys et al., 1996; Sosne et al., 2022; Scientific American, 2026; Vox, 2026]

What it is

TB-500 is the gray-market name most often applied to a synthetic thymosin β4 fragment that FDA currently labels as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500." Secondary reference summaries of the anti-doping and peptide literature describe the marketed fragment more specifically as the N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17 to 23 of the full-length parent. That parent, thymosin β4, is a 43 amino acid endogenous peptide or protein.

How it's proposed to work

For full-length thymosin β4, the best-characterized mechanism is G-actin sequestration. In plain terms, TMβ4 binds monomeric actin and helps regulate the balance between G-actin and F-actin, which matters for cell shape, motility, and migration. The conserved LKKTET motif beginning around residue 17 is repeatedly identified in the literature as part of the actin-interaction region. That said, there is some broader structural work that argues that more of the 43 amino acid chain participates in the actin complex. [Xue et al., 2007]

Separate full-length TMβ4 literature also describes angiogenesis, inflammation modulation, corneal repair signaling, and cardioprotective signaling that includes integrin-linked kinase. Those findings matter because they show that TMβ4 biology is real and multi-lab. They do not erase the fragment versus parent problem. They do not change the fact that the gray-market use case is usually systemic fragment injection sold for musculoskeletal recovery, while the more advanced human development programs used full-length TMβ4 in ophthalmic, topical dermal, or IV formulations for different indications. [Scientific American 4/18/26]

Common forms in circulation

Gray-market injectable fragment vials for self-injection. Multiple 2026 reported pieces describe consumers obtaining TB-500 in vials, pairing it with bacteriostatic water and syringes, and self-injecting it either alone or in stacks. [Scientific American 4/18/26; Vox 4/23/26; Gothamist 4/23/26; The New Yorker 4/6/26]
Reconstituted lyophilized powder. The New Yorker directly reported purchasing powdered peptide vials, plus bacteriostatic water and syringes, and later sending those products for lab testing. [The New Yorker 4/6/26]

Names and aliases

TB-500 / TB500 / thymosin β4 fragment / LKKTETQ fragment. These names are often used loosely and sometimes as if they were interchangeable with full-length TMβ4. They are not. [FDA]
"Wolverine stack." In current media and consumer discourse, this means BPC-157 plus TB-500. It is simply a cultural label, not a clinical one. [Scientific American 4/18/26; The New Yorker 4/6/26]
"Glow" or "KLOW" stacks. Current reporting describes combinations that add GHK-Cu and sometimes KPV to the BPC-157 plus TB-500 pairing. [Scientific American 4/18/26; Gothamist 4/23/26]
Confusion warning. TB-500 is not thymosin α1, also called thymalfasin or Zadaxin, and it is not full-length thymosin β4. Those are distinct compounds with different sequences, parent proteins, and development histories.

Regulatory status

TB-500 has no FDA-approved human indication. FDA's current peptide safety page, updated April 22, 2026, no longer places "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" in the active Category 2 table. Instead, it now appears under "bulk drug substances nominated but withdrawn." FDA's stated concern for TB-500 is still substantive: potential immunogenicity from aggregation and peptide-related impurities, plus the absence of human exposure data and insufficient safety information to know whether the drug would cause harm if administered to humans [FDA]. This change is procedural, not scientific and not permissive. Removal from the active Category 2 table because a nomination was withdrawn is not approval. It is not placement into Category 1. It does not by itself authorize compounding. [FDA; STAT 4/15/26]

On July 23, 2026, the Pharmacy Compounding Advisory Committee met to reconsider TB-500 free base and acetate for potential inclusion on the 503A Bulks List, evaluating the substances for wound healing. FDA staff had recommended against inclusion, concluding that the substances were not well characterized, historical compounding use was unclear, no human administration data or in vivo wound-healing studies had been identified, and clinical and nonclinical safety information was insufficient. The committee nonetheless voted 8-6, with one abstention, to recommend adding both TB-500 free base and TB-500 acetate to the 503A Bulks List. [FDA 7/23-24/26 PCAC; FDA TB-500 briefing document; Reuters 7/23/26]

The recommendation is advisory only: FDA has not added either substance to the 503A Bulks List, and the vote does not itself authorize compounding, establish safety or efficacy, or constitute FDA approval. The gap between FDA staff's assessment and the committee's vote is itself a relevant fact for readers weighing how settled this status is. [FDA 7/23-24/26 PCAC; FDA TB-500 briefing document]

Purported benefits, by evidence strength

Benefit category	Tier	What the evidence actually says	Source
Soft-tissue, tendon, ligament, muscle repair	Mechanistic/in vitro for the claimed use. No identified human or in vivo wound-healing evidence for TB-500 free base or acetate.	This is the main gray-market sales claim for injected TB-500, often stacked with BPC-157 as "Wolverine." FDA's 2026 review identified no human administration studies and no in vivo wound-healing studies for TB-500 free base or acetate. In an in vitro scratch-wound assay, TB-500 free base did not induce wound healing; one metabolite, N-acetylated LKKTE, appeared active, but that result has not been shown to transfer to the parent fragment.	[FDA TB-500 briefing document] [WSJ 4/20/26] [Time 2/24/26] [Guardian 2/5/26] [New Yorker 4/6/26]
Corneal and ophthalmic wound healing, including dry eye and neurotrophic keratopathy	Clinical trial, but for full-length TMβ4, not the injected fragment.	This is the strongest human anchor in the TMβ4 story. It belongs to the full-length molecule in ophthalmic formulation, not to injected Ac-LKKTETQ sold as TB-500.	Gray-market injectable gap confirmed by [WSJ 4/20/26] [Vox 4/23/26]
Dermal wound healing, including pressure ulcers and burns	Early clinical for full-length TMβ4 topical, not the injected fragment.	The human-development story around dermal healing appears to sit with topical full-length TMβ4 programs, not with injected TB-500 fragment products.	Distinction from gray-market injected peptide supported by [Guardian 2/5/26] [WSJ 4/20/26]
Cardiac repair after myocardial infarction	Animal model plus early human safety only, and again for full-length TMβ4, not the injected fragment.	The cardiac-repair story belongs to the full-length TMβ4 program and to animal studies, with a separate early human safety track for IV development. That is not the same thing as saying injected TB-500 fragment helps musculoskeletal recovery.	Evidence gap for consumer injected peptides confirmed by [Vox 4/23/26] [WSJ 4/20/26]
Anti-inflammatory effects, broad	Animal model and mechanistic hypothesis	Current peptide coverage shows anti-inflammation as one of the common gray-market talking points, but the same coverage also stresses that most of these claims are not supported by meaningful human trials in the marketed use case.	[Guardian 2/5/26] [Time 2/24/26] [WSJ 4/20/26]
Hair growth and cosmetic "glow"	Anecdotal or community reported	This belongs to influencer and gray-market peptide culture, not to a robust TB-500 clinical evidence base. Reporting on the peptide wave shows "glow up" language, skin, hair, and cosmetic claims circulating online, but experts in that reporting say the benefits are overblown and often unsupported by clinical trial data.	[Guardian 3/31/26] [Time 2/24/26]
Anti-aging and longevity	Anecdotal or community reported	The longevity pitch comes from the broader peptide craze. Reporting names TB-500 among the peptides sold into the anti-aging market, but experts quoted in those pieces say the category lacks meaningful human evidence and that people are often "taking them on blind faith."	[Time 2/24/26] [Vox 4/23/26] [Guardian 2/5/26]
Anti-tumor or cancer-related framing	Mechanistic hypothesis only, and off-limits for marketing	Current reporting on peptides repeatedly frames tissue-growth and angiogenesis concerns as part of the risk story. Physicians quoted in mainstream reporting explicitly worry about unknown cancer risk or about promoting growth in occult tumors. That does not make TB-500 an anticancer therapy.	[WSJ 4/20/26] [Guardian 2/5/26] [Vox 4/23/26]

Key literature

Van Troys M, Dewitte D, Goethals M, Carlier MF, Vandekerckhove J, Ampe C. The actin binding site of thymosin beta 4 mapped by mutational analysis. EMBO J. 1996;15(2):201-10. Maps the actin-binding site of full-length thymosin β4 by mutational analysis; the LKKTET region sits inside the actin-binding domain of the parent protein — the cleanest molecular basis for why the TB-500 fragment exists at all.

Zhou B, Honor LB, Ma Q, et al. Thymosin beta 4 treatment after myocardial infarction does not reprogram epicardial cells into cardiomyocytes. J Mol Cell Cardiol. 2012;52(1):43-47. In a mouse myocardial infarction model, thymosin β4 treatment did not reprogram epicardial cells into cardiomyocytes — an important guardrail against "regeneration" language.

Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. Supports full-length thymosin β4's role in corneal wound healing and inflammation in an alkali-injury model.

Sosne G, Kleinman HK, Springs C, Gross RH, Sung J, Kang S. 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci. 2022;24(1):554. One of the strongest human anchors in the thymosin β4 evidence base: a randomized, placebo-controlled, double-masked Phase III trial in neurotrophic keratopathy reported complete healing after 4 weeks in 6 of 10 treated subjects versus 1 of 8 on placebo (p = 0.0656).

Nguyen J, Verma S, Vuong VT, Queener H, Coulson-Thomas VJ, Gesteira TF. Engineered Tandem Thymosin Peptide Promotes Corneal Wound Healing. Invest Ophthalmol Vis Sci. 2025;66(14):31. Shows that thymosin-derived corneal wound-healing research is still active, using an engineered tandem thymosin peptide.

References

Scientific American, April 18, 2026 — "Peptides promise longevity and healing. Does the science back them up?"
Scientific American, April 15, 2026 — "The Trump administration is looking to experts to weigh in on peptides"
STAT, April 6, 2026 — "What the peptide craze reveals about Americans' relationship with risk"
STAT, April 15, 2026 — "FDA peptide advisers expected to support RFK Jr.'s legalization push"
ProPublica, April 3, 2026 — "RFK Jr. May Reverse a Peptide Ban He Calls 'Illegal.' Former FDA Officials Say He Mischaracterized Their Work."
The New Yorker, April 13, 2026 — "Why Are People Injecting Themselves with Peptides?"
Vox, April 23, 2026 — "Please don't inject yourself with bootleg peptides"
The Guardian, February 5, 2026 — "'People are turning themselves into lab rats': the injectable peptides craze sweeping the US"
The Guardian, April 4, 2026 — "What are peptides, are they safe and is there evidence to back up the hype?"
The Washington Post, November 26, 2025 — "Some celebrities swear by peptides, but doctors warn of serious risks"
The Wall Street Journal, April 20, 2026 — "Injectable Peptides Are the Latest TikTok Wellness Fad. Doctors Are Worried."
Business Insider, April 25, 2026 — "Peptides are getting the DIY treatment. Doctors are concerned."
Time, March 2026 — "What to Know About the 'Anti-Aging' Peptide Shots Flooding Social Media"
U.S. Food and Drug Administration — "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks"
U.S. Food and Drug Administration — FDA Briefing Document for TB-500-Related Bulk Drug Substances, July 23-24, 2026 PCAC meeting.
Reuters, July 23, 2026 — "FDA advisory panel votes to place popular peptide TB-500 on compounding list"
World Anti-Doping Agency — "The Prohibited List"

‍

TB-500